Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Could Launch US Bevacizumab This Year Despite Patent Thicket

Executive Summary

Pfizer has secured FDA approval for its Zirabev becacizumab biosimilar. But Genentech is citing 22 patents it says should bar the rival to its Avastin oncology brand.

You may also be interested in...



US Insurer United Rewards Amgen’s Early Entry With Bevacizumab And Trastuzumab

Amgen’s Mvasi and Kanjinti alternatives to Roche’s Avastin bevacizumab and Herceptin trastuzumab brands will from 1 October be preferred by plans administered by the largest US health insurer, UnitedHealthcare.

Biopharma Rises For Pfizer Ahead Of Biosimilars Launches And Mylan Merger

As Pfizer prepares for biosimilars launches in the US, its Biopharma unit has enjoyed 3% growth in the first half of 2019.

FDA Approves Pfizer's Ruxience Rituximab Biosimilar

Pfizer has received approval from the US Food and Drug Administration for the country’s second biosimilar rituximab, under the Ruxience label. However, the company has not yet revealed launch plans for the rival to Roche’s Rituxan brand.

Related Content

Topics

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel